Jean‐Pierre Gotteland

No ORCID on file · 15 papers in corpus · active 2008-2022

Study types

  • article 15

Condition tags

  • endometriosis 11
  • mesh:D004715 5
  • mesh:D017699 2
  • mesh:D004412 1
  • chronic_pelvic_pain 1
  • dysmenorrhea 1
  • dyspareunia 1
article 2022
O-306 LINZAGOLIX FOR ENDOMETRIOSIS-ASSOCIATED PAIN: SAFETY RESULTS FROM EDELWEISS 3, A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
·doi:10.1093/humrep/deac105.103

Abstract Study question Is once-daily linzagolix treatment for women with moderate to severe endometriosis-associated pain (EAP) safe for use for up to 6 months of treatment? Summary answer Both doses of linzagolix were well-tolerated with …

article 2021
A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis
British journal of clinical pharmacology ·doi:10.1111/bcp.15171

AIMS: To identify linzagolix doses, an oral GnRH receptor antagonist, that effectively lower oestradiol (E2) to relieve endometriosis-related pelvic pain without compromising bone health. METHODS: Integrated statistical, pharmacokinetic-pha…

article 2020
Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding—delayed add-back onset does not improve bleeding pattern
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1007/s43032-020-00172-z
article 2020
Linzagolix for Endometriosis-Associated Pain: Lipid Changes After 52 Weeks of Treatment [25B]
·doi:10.1097/01.aog.0000663180.46470.c9

INTRODUCTION: Linzagolix is a new, investigational, non-peptide, GnRH receptor antagonist being developed to treat endometriosis-associated pain (EAP). The EDELWEISS trial was a Phase 2b, double-blind, randomized, placebo-controlled, multic…

article 2020
Quality of Life Results After 52 Weeks of Treatment With Linzagolix for Endometriosis-Associated Pain [30B]
·doi:10.1097/01.aog.0000663200.75027.38

INTRODUCTION: Linzagolix is a new investigational, non-peptide, oral GnRH receptor antagonist being developed to treat endometriosis-associated pain (EAP). The EDELWEISS trial was a Phase 2b, double-blind, randomized, placebo-controlled, mu…

article 2020
Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial
Fertility and sterility ·doi:10.1016/j.fertnstert.2020.02.114
article 2019
Long term treatment of endometriosis associated pain (EAP) with linzagolix: efficacy and safety after 12 months of treatment
·doi:10.1016/j.fertnstert.2019.07.935
article 2019
The Effect of Linzagolix on Bone Mineral Density (BMD): Safety Results From a Dose-Ranging Trial [21J]
·doi:10.1097/01.aog.0000558837.48634.b6

INTRODUCTION: Linzagolix is a new, non-peptide, GnRH receptor antagonist being developed to treat endometriosis-associated pain (EAP). The EDELWEISS trial is a Phase 2b, double-blind, randomized, placebo-controlled, multicenter, dose-rangin…

article 2017
Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109
·doi:10.1210/jc.2017-01875

Context: OBE2109 is a potent, oral gonadotropin-releasing hormone receptor antagonist being developed for the treatment of sex-hormone-dependent diseases in women. Objective: We assessed the pharmacodynamics and safety of OBE2109 alone and …

article 2015
Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719115600553
article 2015
c-Jun NH2-terminal kinase inhibitor bentamapimod reduces induced endometriosis in baboons: an assessor-blind placebo-controlled randomized study
Fertility and sterility ·doi:10.1016/j.fertnstert.2015.11.022
article 2014
Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719114522526
article 2011
Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model
Human Reproduction ·doi:10.1093/humrep/der079

BACKGROUND: Steroid sulfatase (STS) is involved in estrogen biosynthesis and expressed in eutopic and ectopic endometrium of disease-free and endometriosis patients. The present study was designed to investigate its role in endometriosis de…

article 2011
Inhibition of Steroid Sulfatase Decreases Endometriosis in an In Vivo Murine Model
·doi:10.1097/ogx.0b013e31823d8bed

Endometriosis is an estrogen-dependent disorder. Treatment with hormonal therapy suppresses estrogen and leads to regression of lesions. However, hormonal therapy is associated with significant morbidity, adverse effects, and recurrence of …

article 2008
Interruption of Inflammatory Pathways with JNK Inhibitors Induces Regression of Human Endometriotic Lesions and Restores Progesterone Receptor Sensitivity in Endometrium and Lesions.
·doi:10.1093/biolreprod/78.s1.113b

Endometriosis is one of the most common causes of chronic pelvic pain, which affects over 70 million adult and adolescent women worldwide. The pathophysiology of endometriosis involves endocrine, inflammatory and angiogenic components and t…